BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36868501)

  • 1. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
    Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
    Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
    Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
    Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
    Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
    Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
    Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
    Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
    Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
    Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.
    Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC
    Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population.
    Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S
    Curr Med Res Opin; 2021 Sep; 37(9):1555-1561. PubMed ID: 34218725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
    Vaassen P; Dürr NR; Rosenbaum T
    Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.
    Yang X; Yoo HK; Amin S; Cheng WY; Sundaresan S; Zhang L; Duh MS
    Childs Nerv Syst; 2022 Aug; 38(8):1513-1522. PubMed ID: 35579709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.